Selective co-stimulation blockade: CTLA4-Ig (Abatacept);Selektive kostimulationsblockade: CTLA4-Ig (Abatacept)

Zeitschrift fur Rheumatologie

Volumn 69, Issue 7, 2010, Pages 601-607

  Alten, R ^a   Marker Hermann E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Arthritis, rheumatoid; Disease activity; Disease progression; Infection; T cells

Indexed keywords

ABATACEPT; BELATACEPT; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES;

EID: 77957839110     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0533-4     Document Type: Review

References (31)

1. Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 220-228
2. Alten R, Westhovens R, Kremer JM et al (2009) Gleichbleibende Sicherheit und dauerhafte Verbesserung der Krankheitsaktivität und des Therapieansprechens über 7 Behandlungsjahre mit Abatacept bei Biologika-naiven RA-Patienten, DGRh-Kongress, Poster # BI.17
3. Banerjee S, Webber C, Poole AR (1992) The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. Cell Immunol 144:347-357
4. Bigbee CL, Gonchoroff DG, Vratsanos G et al (2007) Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice. Arthritis Rheum 56:8:2557-2565
5. Breedveld FC, Dynesius-Trentham R, de Sousa M et al (1989) Collagen arthritis in the rat is initiated by CD4+ T cells and can be amplified by iron. Cell Immunol 121:1-12
6. Buch MH, Boyle DL, Rosengren S, Saleem B et al (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68:1220-1227
7. Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510-516
8. Emery P, Kosinski M, Li T et al (2006) Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 33:681-6895
9. Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225-1227
10. Genant HK, Peterfy CG, Westhovens R et al (2008) Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 67(8):1084-1089
11. Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67(4):547-554
12. Haggerty HG, Abbott MA, Reilly TP et al (2007) Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 34:2365-2373
13. Kraan MC, Haringman JJ, Weedon H et al (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63:483-488
14. Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263-2271
15. Kremer JM, Westhovens R, Alten R et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915
16. Lenschow DJ, Zeng Y, Thistlethwaite JR et al (1992) Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257:789-792
17. Linsley PS, Brady W, Urnes M et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569
18. Mima T, Saeki Y, Ohshima S, Nishimoto N et al (1995) Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell population s oligoclonally expanding in the rheumatoid joints. J Clin Invest 96:1746-1175
19. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888-898
20. Moreland LW, Alten R, Van den Bosch F et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470-1479
21. Reynolds J, Tam FW, Chandraker A et al (2000) CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 105:643-651
22. Schiff M, Keiserman M, Codding C, Songcharoen S (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096-1103
23. Schiff M, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann Rheum Dis 68:1708-1714
24. Sibilia J, Westhovens R (2007) Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 25(Suppl 46):S46-S56
25. Simon TA, Smitten AL, Franklin J et al (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68:1819-1826
26. Van Boxel JA, Paget SA (1975) Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med 293:517-520
27. Webb LM, Walmsley MJ, Feldmann M (1996) Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26:2320-2328
28. Weinblatt ME, Schiff MH, Goldman A et al (2007) Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 66:228-234
29. Weisman MH, Durez P, Hallegua D et al (2006) Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 33:2162-2166
30. Westhovens R, Kremer JM, Moreland LW et al (2009) Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: A 5-year extended phase IIB study. J Rheumatol 36:736-742
31. Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors, Ann Rheum Dis 68:1870-1877